Evidence map›Paper›PMID 41234933›Full record

ArticleFrontiers in neurology2025

Characterization of a humanized mouse model of Charcot-Marie-Tooth type 1A for the discovery of human

Atsuki Taruta, Shin-Ichi Matsumoto, Yasushi Masuda, Tetsuaki Hiyoshi, Akina Harada, Yohei Kosugi, Masato Nakashima

Abstract read
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Atsuki TarutaNeuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
Shin-Ichi MatsumotoPreclinical and Translational Sciences, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
Yasushi MasudaPreclinical and Translational Sciences, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
Tetsuaki HiyoshiNeuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
Akina HaradaNeuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
Yohei KosugiPreclinical and Translational Sciences, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
Masato NakashimaNeuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Charcot-Marie-Tooth type 1A (CMT1A) is the most common inherited demyelinating peripheral neuropathy caused by duplication of the peripheral myelin protein 22 ( Methods: Heterozygous (hetero-humanized) and homozygous (homo-humanized) Results: Homo-humanized mice exhibited abnormal mRNA expression of myelin-related genes, slow nerve conduction velocity, reduced compound muscle action potential, demyelinated peripheral nerves, higher levels of plasma neurofilament light chain, muscle weakness and motor/balance disabilities, alterations in electrical impedance myography, and muscle fiber atrophy. In contrast, the hetero-humanized mice did not display any of the previously described impairments. Interpretation: Homo-humanized mice reflect various aspects of CMT1A characteristics in an

Indexed as

Charcot–Marie-Tooth type 1Ademyelinationelectrophysiologyhumanized modelmuscle deteriorationPMP22

Identifiers

PMID41234933
PMCPMC12606582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.